RO-28-2653

RO-28-2653 is an orally active matrix metalloproteinase (MMP) inhibitor. RO-28-2653 exhibits highly selective inhibitory effects on MMP2, MMP9 and membrane-type 1-MMP, and may reduce side effects (such as musculoskeletal pain) compared to broad-spectrum MMP inhibitors. RO-28-2653 shows significant tumor growth inhibition in a rat prostate model. RO-28-2653 can be used in studies of hormone-sensitive tumors[1][2].

Product Specifications

CAS Number

[261956-22-3]

UNSPSC

12352005

Target

MMP

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

O=C1NC(C(N2CCN(C3=CC=C([N+]([O-])=O)C=C3)CC2)(C4=CC=C(C5=CC=CC=C5)C=C4)C(N1)=O)=O

Molecular Formula

C26H23N5O5

Molecular Weight

485.49

References & Citations

[1]Abramjuk C, et al. Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. Anticancer Drugs. 2005 Sep;16 (8) :855-61.|[2]iette M, et al. Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. Eur J Pharm Sci. 2006 Jun;28 (3) :189-95.